|
General Healthcare
125 million Americans have 1 or more
chronic conditions (e.g. congestive heart failure,
diabetes.) Chronic diseases account for 75% of all health
care expenditures.
Source: Burrill & Company, 2006
Source: AdvaMed 2006
The market for coatings and surface-treatment processes
used on medical devices will reach more than $5.31 billion
by 2010. The 12.4% annual growth rate will be fueled by
explosive growth in high-value combination products.
Source: Medical Device Coatings
Report, BCC Research, April 2006
During period of 2001-1006, California companies - $23.9
billion of increased market value creation, followed by
Indiana at $22.9 billion, and Massachusetts at $20.7
billion.
Source: Medical Device Industry
Market Capitalization Report, 2001-2006.
The medical devices and equipment industry employs more
than 411,400 workers, accounting for nearly one third of
all US bioscience jobs.
Source: Medical Product Outsourcing
2006
Pennsylvania and New York included in Top
5 US states for Medical Device Employment - The thriving
medical device industry in Massachusetts is the East Coast
equivalent of the San Francisco Bay Area.
Source: US Bureau of Labor
Statistics, 2005
The spinal devices segment (of the marketplace), with a
striking growth rate of 20 to 25 percent annually, leads
the orthopedic market. Extensive research on bone growth
factors and fusion biologics has been integral to emerging
technologies for the spine market. Source: Frost &
Sullivan’s Emerging Technologies for the Spine Market
(Technical Insights), published September 2006
Combination Products
The combination products market is estimated at $5.9B in
2004, and will continue to grow at a compound annual rate
of 10% through 2009. By 2009, the market is expected to
reach approximately $9.5B worldwide with a majority of
these revenues from drug-eluting stents and
steroid-eluting electrodes.
Source: Navigant Consulting, Inc.
"Combination products have the regulatory flexibility to
apply the most appropriate regulation to a combination
product by tailoring the approach to taking pieces of drug
regulation, pieces of device regulation, or biologics, as
appropriate."
Source: Mark Kramer, Director of
the FDA’s Office of Combination Products, September 2006.
In 2004, the US held approximately 65% of the drug-device
combination product market. By 2010, the US is projected
to hold 57%.
Source: Business Communications
Inc.
Cardiovascular related combination product revenues will
account for approximately 88% of worldwide sales in 2009.
A majority of these revenues will be due to drug-eluting
stent sales while steroid eluting electrode and waterjet
device revenues account for the remainder.
Source: Front Line Strategic
Consulting, Inc.
|
